Colin W G Fishwick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7795214/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	pH as a Trigger of Peptide β-Sheet Self-Assembly and Reversible Switching between Nematic and Isotropic Phases. Journal of the American Chemical Society, 2003, 125, 9619-9628.	6.6	441
2	Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nature Genetics, 2008, 40, 789-793.	9.4	267
3	Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nature Communications, 2016, 7, 12406.	5.8	202
4	Structures of Helical β-Tapes and Twisted Ribbons:  The Role of Side-Chain Interactions on Twist and Bend Behavior. Nano Letters, 2003, 3, 1475-1479.	4.5	134
5	Structure-based discovery of antibacterial drugs. Nature Reviews Microbiology, 2010, 8, 501-510.	13.6	122
6	Adsorption and Self-Assembly of Peptides on Mica Substrates. Angewandte Chemie - International Edition, 2005, 44, 1965-1968.	7.2	112
7	Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical Prevalence. Antimicrobial Agents and Chemotherapy, 2006, 50, 298-309.	1.4	111
8	Assay Platform for Clinically Relevant Metallo-Î ² -lactamases. Journal of Medicinal Chemistry, 2013, 56, 6945-6953.	2.9	100
9	High-Risk Human Papillomavirus E5 Oncoprotein Displays Channel-Forming Activity Sensitive to Small-Molecule Inhibitors. Journal of Virology, 2012, 86, 5341-5351.	1.5	95
10	Cyclic Boronates Inhibit All Classes of \hat{l}^2 -Lactamases. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	94
11	RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2000, 44, 3163-3166.	1.4	86
12	Structure-Based Design, Synthesis, and Characterization of Inhibitors of Human and <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenases. Journal of Medicinal Chemistry, 2009, 52, 2683-2693.	2.9	84
13	Self-assembling β-Sheet Tape Forming Peptides. Supramolecular Chemistry, 2006, 18, 435-443.	1.5	80
14	Molecular mechanism of ligand recognition by membrane transport protein, Mhp1. EMBO Journal, 2014, 33, 1831-1844.	3.5	79
15	Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques. Antimicrobial Agents and Chemotherapy, 2004, 48, 4366-4376.	1.4	77
16	The nature of <i>Staphylococcus aureus</i> MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Molecular Microbiology, 2009, 72, 335-343.	1.2	75
17	Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium, 2012, 51, 1-11.	1.1	72
18	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 88-92.	1.0	69

#	Article	IF	CITATIONS
19	Structure-switching M ₃ L ₂ Ir(<scp>iii</scp>) coordination cages with photo-isomerising azo-aromatic linkers. Chemical Science, 2018, 9, 8150-8159.	3.7	69
20	Linezolid and Tiamulin Cross-Resistance in <i>Staphylococcus aureus</i> Mediated by Point Mutations in the Peptidyl Transferase Center. Antimicrobial Agents and Chemotherapy, 2008, 52, 1737-1742.	1.4	67
21	Determinants of Hepatitis C Virus p7 Ion Channel Function and Drug Sensitivity Identified In Vitro. Journal of Virology, 2009, 83, 7970-7981.	1.5	62
22	Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology, 2011, 54, 79-90.	3.6	62
23	Design and Synthesis of Potent Inhibitors of the Malaria Parasite Dihydroorotate Dehydrogenase. Journal of Medicinal Chemistry, 2007, 50, 186-191.	2.9	60
24	Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine. Nature Communications, 2017, 8, 1939.	5.8	59
25	Stereoselective Palladium-Catalyzed Four-Component Cascade Synthesis of Pyrrolidinyl-, Pyrazolidinyl-, and Isoxazolidinyl Isoquinolines. Angewandte Chemie - International Edition, 2005, 44, 7570-7574.	7.2	57
26	Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness. Nature Chemical Biology, 2014, 10, 457-462.	3.9	50
27	A short dipolar cycloaddition approach to Î ³ -lactam alkaloids from cynometra hankei. Tetrahedron Letters, 1996, 37, 3915-3918.	0.7	48
28	Factors Influencing the Specificity of Inhibitor Binding to the Human and Malaria Parasite Dihydroorotate Dehydrogenases. Journal of Medicinal Chemistry, 2012, 55, 5841-5850.	2.9	47
29	Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity. European Journal of Medicinal Chemistry, 2014, 86, 31-38.	2.6	45
30	1,3-Dipolar cycloaddition of stabilised and non-stabilised azomethine ylides derived from uracil polyoxin C (UPoC): access to nikkomycin analogues. Tetrahedron, 2004, 60, 3473-3485.	1.0	44
31	Natural and synthetic flavonoid modulation of TRPC5 channels. British Journal of Pharmacology, 2016, 173, 562-574.	2.7	42
32	Design and synthesis of new hydroxyethylamines as inhibitors of d-alanyl-d-lactate ligase (VanA) and d-alanyl-d-alanine ligase (DdlB). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1376-1379.	1.0	41
33	A De Novo Designed Inhibitor ofD-Ala-D-Ala Ligase fromE. coli. Angewandte Chemie - International Edition, 2005, 44, 6403-6406.	7.2	40
34	Enantioselective synthesis of non-proteinogenic 2-arylallyl-α-amino acids via Pd/In catalytic cascades. Tetrahedron, 2006, 62, 12159-12171.	1.0	40
35	New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Scientific Reports, 2016, 6, 29179.	1.6	40
36	In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-Î ² -lactamase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 1255-1260.	2.9	40

#	Article	IF	CITATIONS
37	Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme mur D. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1557-1560.	1.0	39
38	Structural/mechanistic insights into the efficacy of nonclassical βâ€lactamase inhibitors against extensively drug resistant <i>Stenotrophomonas maltophilia</i> clinical isolates. Molecular Microbiology, 2017, 106, 492-504.	1.2	39
39	New insights into the binding mode of pyridine-3-carboxamide inhibitors of E. coli DNA gyrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3546-3550.	1.4	39
40	Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. Journal of Antimicrobial Chemotherapy, 2009, 63, 1112-1117.	1.3	38
41	Affimer proteins inhibit immune complex binding to Fcl̂³RIIIa with high specificity through competitive and allosteric modes of action. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E72-E81.	3.3	36
42	An efficient route to S-N-(9-fluorenylmethoxycarbonyl)-4′-(1-azi-2,2,2-trifluoroethyl)phenylalanine. Tetrahedron Letters, 1994, 35, 4611-4614.	0.7	35
43	2-Aminotetralones: Novel inhibitors of MurA and MurZ. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1730-1734.	1.0	32
44	The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen I± chain. Blood, 2013, 121, 2117-2126.	0.6	31
45	A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Letters, 2017, 393, 16-21.	3.2	31
46	A simple route to C-functionalised azaxylylenes and diazaxylylenes. Journal of the Chemical Society Chemical Communications, 1984, , 1304.	2.0	30
47	Novel synthesis of calamitic and discotic liquid crystalline derivatives of tetrathiafulvalene (TTF). Chemical Communications, 1998, , 113-114.	2.2	30
48	Structure-Based Identification and Characterization of Inhibitors of the Epilepsy-Associated KNa1.1 (KCNT1) Potassium Channel. IScience, 2020, 23, 101100.	1.9	29
49	The First de Novo-Designed Antagonists of the Human NK2Receptor. Journal of Medicinal Chemistry, 2005, 48, 5655-5658.	2.9	28
50	Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6770-6774.	1.0	28
51	Structure Guided Development of Potent Reversibly Binding Penicillin Binding Protein Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 219-223.	1.3	28
52	Activity of and Development of Resistance to Corallopyronin A, an Inhibitor of RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2011, 55, 2413-2416.	1.4	28
53	Studies on the inhibition of AmpC and other β-lactamases by cyclic boronates. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 742-748.	1.1	28
54	Highly efficient diastereoselective Exo Diels-Alder reactions of homochiral 2-(N-acylamino)-1-thia-1,3-dienes: A powerful entry into optically pure thiopyrans. Tetrahedron Letters, 1996, 37, 123-126.	0.7	26

#	Article	IF	CITATIONS
55	Discovery of novel FabF ligands inspired by platensimycin by integrating structure-based design with diversity-oriented synthetic accessibility. Organic and Biomolecular Chemistry, 2014, 12, 486-494.	1.5	25
56	The First Small-Molecule Inhibitors of Members of the Ribonuclease E Family. Scientific Reports, 2015, 5, 8028.	1.6	25
57	Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase. Tetrahedron, 2008, 64, 10049-10054.	1.0	23
58	Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century. Drug Discovery Today, 2015, 20, 1018-1026.	3.2	23
59	X-ray and cryo-EM structures of inhibitor-bound cytochrome <i>bc</i> ₁ complexes for structure-based drug discovery. IUCrJ, 2018, 5, 200-210.	1.0	23
60	Three-component bimetallic (Pd/In) mediated cascade allylation of C=X functionality. Journal of Organometallic Chemistry, 2003, 687, 483-493.	0.8	22
61	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes part III: Control of diastereoselectivity using homochiral auxiliaries. Tetrahedron, 1998, 54, 3219-3234.	1.0	21
62	Structureâ€based design of antiâ€infectives. Annals of the New York Academy of Sciences, 2010, 1213, 20-45.	1.8	21
63	Benzothioxalone derivatives as novel inhibitors of UDP-N-acetylglucosamine enolpyruvyl transferases (MurA and MurZ). Journal of Antimicrobial Chemotherapy, 2010, 65, 2566-2573.	1.3	21
64	Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Frontiers in Cellular and Infection Microbiology, 2020, 10, 203.	1.8	21
65	Identification of Selective Inhibitors of the Potassium Channel Kv1.1–1.2 ₍₃₎ by Highâ€Throughput Virtual Screening and Automated Patch Clamp. ChemMedChem, 2012, 7, 1775-1783.	1.6	20
66	Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli. Biomolecules, 2020, 10, 899.	1.8	20
67	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet, The, 2015, 385, S57.	6.3	19
68	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes. Tetrahedron Letters, 1989, 30, 4449-4452.	0.7	18
69	Dithiolane-isocyanate imminium methylides: A rapid stereoselective entry into Î ³ -lactams. Tetrahedron Letters, 1995, 36, 9409-9412.	0.7	18
70	Applications of structure-based design to antibacterial drug discovery. Bioorganic Chemistry, 2014, 55, 69-76.	2.0	18
71	[3+2] Cycloadditions of indolenine-derived azomethine ylides a rapid entry into pyrrolo [1,2-a] indolines Tetrahedron Letters, 1988, 29, 5325-5328.	0.7	17
72	Facile intramolecular cycloadditions of 2-(N-Acylamino)-1-thia-1,3-dienes. Tetrahedron Letters, 1991, 32, 405-408.	0.7	17

#	Article	IF	CITATIONS
73	A study of the effects of substituents on the selectivity of the binding of N-arylaminomethylene malonate inhibitors to DHODH. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1284-1287.	1.0	17
74	Furanyl-Rhodanines Are Unattractive Drug Candidates for Development as Inhibitors of Bacterial RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2010, 54, 4506-4509.	1.4	17
75	Structure-Based Ligand Design of Novel Bacterial RNA Polymerase Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 729-734.	1.3	17
76	Generation and cycloadditions of 2-(N-Acylamino)-1-thia-1,3-dienes. Part II. Rationalization of reactivity using an FMO approach Tetrahedron, 1989, 45, 7879-7898.	1.0	16
77	Discovery of Biphenylacetamide-Derived Inhibitors of BACE1 Using de Novo Structure-Based Molecular Design. Journal of Medicinal Chemistry, 2013, 56, 1843-1852.	2.9	16
78	Encapsulation of sodium alkyl sulfates by the cyclotriveratrylene-based, [Pd ₆ L ₈] ¹²⁺ stella octangula cage. Dalton Transactions, 2014, 43, 5657-5661.	1.6	16
79	From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 1481-1504.	2.9	16
80	Facile preparation of 2-imino tetrahydrofurans, pyrans and oxepans. Tetrahedron Letters, 1989, 30, 6571-6572.	0.7	15
81	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones. Tetrahedron Letters, 1994, 35, 6551-6554.	0.7	15
82	Hetero-1,3-dipolar cycloadditions of dithiolane-isocyanate imminium methylides: A novel route to 1,3-oxazolidine- and thiazolidine-2-thiones. Tetrahedron Letters, 1996, 37, 711-714.	0.7	15
83	Computational Methods to Identify New Antibacterial Targets. Chemical Biology and Drug Design, 2015, 85, 22-29.	1.5	15
84	A facile palladium catalysed 3-component cascade route to functionalised isoquinolinones and isoquinolines. Chemical Communications, 2016, 52, 164-166.	2.2	15
85	Generation and cycloadditions of tetrahydrofuryl, pyranyl, and oxepanyl-2-imminium methylides. Tetrahedron Letters, 1989, 30, 6573-6576.	0.7	14
86	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1, 3-dienes. Structural investigations using NMR methods. Part I Tetrahedron, 1989, 45, 6771-6790.	1.0	14
87	Intramolecular [3+2] cycloadditions of non-stabilised azomethine imidate-methylides. Tetrahedron Letters, 1989, 30, 4443-4446.	0.7	14
88	The azomethine ylide strategy for β-lactam synthesis. An evaluation of alternative pathways for azomethine ylide generation. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1281-1289.	1.3	14
89	CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Frontiers in Cellular and Infection Microbiology, 2018, 8, 352.	1.8	14
90	Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. Antiviral Research, 2018, 156, 46-54.	1.9	14

#	Article	IF	CITATIONS
91	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones and the highly diastereoselective Diels-Alder reactions of 4-vinyl-1,2-isothiazoline-3-one-1-oxides. Tetrahedron, 1999, 55, 12313-12330.	1.0	13
92	Spatial requirements of the antagonist binding site of the NK2 receptor. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 819-822.	1.0	13
93	Pd(0) catalyzed three–five-component C-2-arylallylation of active methylene heterocycles: pyrazolones, oxazolones, isoxazolones and N,Nâ€2-dimethylbarbituric acid. Tetrahedron, 2007, 63, 7213-7228.	1.0	13
94	XY–ZH compounds as potential 1,3-dipoles. Part 65: atom economic cascade synthesis of highly functionalized pyrimidinylpyrrolidines. Tetrahedron, 2011, 67, 5700-5710.	1.0	13
95	(±) cis-bisamido epoxides: A novel series of potent FXIII-A inhibitors. European Journal of Medicinal Chemistry, 2015, 98, 49-53.	2.6	13
96	Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led <i>de Novo</i> Design. ACS Medicinal Chemistry Letters, 2017, 8, 1264-1268.	1.3	13
97	Catalytic bimetalic [Pd(0)/Ag(I) Heck-1,3-dipolar cycloaddition cascade reactions accessing spiro-oxindoles. Concomitant in situ generation of azomethine ylides and dipolarophile. Tetrahedron, 2018, 74, 3564-3577.	1.0	13
98	The synthesis and reactivity of optically pure amino acids bearing side-chain thioamides. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 3227-3231.	1.3	12
99	In Silico Design and Biological Evaluation of a Dual Specificity Kinase Inhibitor Targeting Cell Cycle Progression and Angiogenesis. PLoS ONE, 2014, 9, e110997.	1.1	12
100	Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR–IGF1R hybrid receptor modulators. RSC Medicinal Chemistry, 2022, 13, 360-374.	1.7	12
101	Intramolecular [3+2] cycloaddition versus 1,4-hydrogen shift in indolium-N-methylides. Tetrahedron Letters, 1989, 30, 4447-4448.	0.7	11
102	Neighbouring group effects in a Pummerer-type rearrangement: A facile entry into 3,1-benzoxathiins. Tetrahedron, 1995, 51, 6819-6834.	1.0	10
103	Adenosine Tetraphosphoadenosine Drives a Continuous ATP-Release Assay for Aminoacyl-tRNA Synthetases and Other Adenylate-Forming Enzymes. ACS Chemical Biology, 2013, 8, 2157-2163.	1.6	10
104	Hyperreactivity of adenines and conformational flexibility of a translational repression site. FEBS Letters, 1991, 283, 159-164.	1.3	9
105	Cyclic-fused azomethine-, imidate-, and thioimidate methylides: An efficient regiocontrolled entry into spiro-fused pyrrolidines. Tetrahedron Letters, 1996, 37, 5163-5166.	0.7	9
106	Selective Phosphonylation of 5′-Adenosine Monophosphate (5′-AMP) via Pyrophosphite [PPi(III)]. Origins of Life and Evolution of Biospheres, 2016, 46, 425-434.	0.8	9
107	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, 2021, 106, 1616-1623.	1.7	9

108 ortho-Quinonoid compounds. , 0, , 403-453.

#	Article	IF	CITATIONS
109	Remarkably high diastereoselective exo diels-alder reactivity of 4-vinyl isothiazoline-3-one-1-oxides: The sulphoxide Syn effect Tetrahedron Letters, 1995, 36, 7713-7716.	0.7	8
110	X=Y–ZH system as potential 1,3-dipoles. Part 59: Cascade 1,3-azaprotio cyclotransfer–1,3-dipolar cycloaddition (1,3-APT–1,3-DC) reactions of benzobicyclo[3.3.1]non-5-en-9-one oxime. Tetrahedron, 2003, 59, 9997-10007.	1.0	8
111	Î ³ -Carboline AC190 analogues via palladium catalysed allene insertion stereo and regioselective 3- and 5-component cascades. Tetrahedron, 2016, 72, 1316-1329.	1.0	8
112	Photoactivatable analogues of a Substance P non-peptidic antagonist, for probing the antagonist binding site of the NK1 receptor. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1271-1274.	1.0	7
113	A Simple and Efficient Preparation of 3-Aryl-3-Trifluoromethyl-3H-Diazirinyl Sulfoxides and Sulfones. Synthesis, 1995, 1995, 553-556.	1.2	7
114	The azomethine ylide strategy for β-lactam synthesis. A comprehensive mechanistic evaluation. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1270-1280.	1.3	7
115	Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease. Antiviral Research, 2015, 117, 20-26.	1.9	7
116	Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment. ACS Medicinal Chemistry Letters, 2020, 11, 605-610.	1.3	7
117	New Opportunities in the Structure-based Design of Anti-Protozoan Agents. Current Topics in Medicinal Chemistry, 2016, 17, 79-90.	1.0	7
118	Formation and mechanistic implication of a novel thiaazabicyclooctane derivative drug the cycloaddition of n-acetyl cinnamic acid thioamide. Tetrahedron Letters, 1991, 32, 2529-2532.	0.7	6
119	Neighbouring group participation in Pummerer-type rearrangements of ortho-substituted arylmethyl sulphoxides. Tetrahedron Letters, 1995, 36, 2299-2302.	0.7	6
120	Two novel amino acid derivatives containing side-chain thioamides for the synthesis of photoactivatable peptides. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 715-718.	1.0	6
121	Preparation of novel 3H-trifluoromethyldiazirine-based photoactivatable potassium channel antagonists. Tetrahedron, 2005, 61, 11244-11252.	1.0	6
122	Preparation of methyl-2-(ï‰-iodoalkyl)propenoates and a facile route to 2-carbomethoxy-1,3-butadiene. Tetrahedron Letters, 1989, 30, 5653-5654.	0.7	5
123	Detection and mechanistic implication of a dynamic equilibrium in some novel spiro-heterocyclic systems. Tetrahedron Letters, 1989, 30, 6777-6780.	0.7	5
124	Structure-Guided Enhancement of Selectivity of Chemical Probe Inhibitors Targeting Bacterial Seryl-tRNA Synthetase. Journal of Medicinal Chemistry, 2019, 62, 9703-9717.	2.9	5
125	A Non-peptidic photoactivatable antagonist for mapping the antagonist binding site of the tachykinin NK2 receptor. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 605-608.	1.0	4
126	Exploitation of a novel allosteric binding region in DNA gyrase and its implications for antibacterial drug discovery. Future Medicinal Chemistry, 2021, 13, 2125-2127.	1.1	4

#	Article	IF	CITATIONS
127	A CONVENIENT PREPARATION OF ETHYL 3,3 DIMETHYL-3H-INDOLE-2-CARBOXYLATE. Organic Preparations and Procedures International, 1990, 22, 766-768.	0.6	3
128	A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT. Molecular Membrane Biology, 2013, 30, 184-194.	2.0	3
129	Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease. Antiviral Research, 2015, 124, 54-60.	1.9	3
130	Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modes. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3878-3882.	1.0	3
131	The Preparation of a 3â€2-(2-Cyanoethyl)phosphoramidite of 5â€2-O-(3-Thiopropyl)methylphosphorylthymidine. Nucleosides & Nucleotides, 1995, 14, 1785-1794.	0.5	2
132	A Simple, One-Pot Synthesis of N-Alkyl and N-Aryl Thieno[2,3-d]pyrimidinones from Thiophene- and Benzothiophene-2-yl-ureas. Synthetic Communications, 2013, 43, 337-344.	1.1	2
133	An in silico structure-based approach to anti-infective drug discovery. Parasitology, 2014, 141, 17-27.	0.7	2
134	<i>Tris</i> - <i>N</i> -alkylpyridinium-functionalised cyclotriguaiacylene hosts as axles in branched [4]pseudorotaxane formation. Supramolecular Chemistry, 2017, 29, 430-440.	1.5	2
135	Identification of Receptor Tyrosine Kinase Inhibitors Using Cell Surface Biotinylation and Affinity Isolation. Methods in Molecular Biology, 2015, 1332, 121-131.	0.4	1
136	Three-Component Bimetallic (Pd/In) Mediated Cascade Allylation of C=X Functionality. Part 1. Scope and Class 1 Examples with Aldehydes and Ketones ChemInform, 2004, 35, no.	0.1	0